SCHEMBL8364952

SCHEMBL8364952

COC(=O)/C(=C\c1cccc(N)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
MAPT P10636 1/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 2/20 0.37
AKR1B1 P15121 1/20 0.35
CYP19A1 P11511 1/20 0.35
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MIF P14174 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5140504 1.00 NPSR1 (0.38) NPSR1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5140506 1.00 NPSR1 (0.38) NPSR1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL13125661 0.87 MIF (0.40) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL2808690 0.87 MIF (0.40) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL2808687 0.87 MIF (0.40) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL8364996 0.85 SMN1; SMN2 (0.40) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL4883097 0.85 SMN1; SMN2 (0.40) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL13906650 0.84 LMNA (0.44) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL3914295 0.83 NPSR1 (0.45) NPSR1SMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL3914299 0.83 NPSR1 (0.45) NPSR1SMN1; SMN2MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-7312360-B2 Substituted hydroxyethylamines ELAN PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
WO-2003050073-A1 SUBSTITUTED HYDROXYETHYLAMINES ELAN PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME NPSR1 861/4885RAB9A 818/4885SMN1; SMN2 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.